This inventor holds 22 USPTO granted patents and 5 published patent applications, primarily in Enzyme Engineering. Top assignee: Inscripta, Inc.. Active years: 2020-2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2020-2024
Areas of Expertise:
Title: Innovations by Benjamin Mijts: A Pioneer in the Field of Enzyme Engineering
Introduction
Benjamin Mijts, based in Boulder, CO, is a prolific inventor with an impressive portfolio of 22 patents. His innovative work primarily focuses on enzyme engineering and nucleic acid technologies, contributing significantly to advancements in biotechnology.
Latest Patents
Among his latest patents is a novel engineered enzyme that features a catalytically inactive MAD7 nuclease (dMAD7). This innovative enzyme retains the ability to bind DNA in a sequence-specific manner, showcasing its potential for various applications in genetic engineering. Another notable patent revolves around engineered nucleic acid-guided nickases, providing optimized scaffolds for making rational, direct edits to nucleic acids in live cells. These patents not only highlight his creativity but also underline his dedication to pushing the boundaries of scientific research.
Career Highlights
Benjamin Mijts works at Inscripta, Inc., a company known for its focus on innovative genetic engineering solutions. His career is marked by a commitment to advancing the field of biotechnology through groundbreaking research and development. With 22 patents under his name, he has become an influential figure in the industry, inspiring others in the field of enzyme development and genetic modification.
Collaborations
Throughout his career, Benjamin has collaborated with notable colleagues such as Juhan Kim and Aamir Mir. These partnerships have fostered an environment of innovation and shared expertise, leading to significant advancements in the technologies they develop. Their combined knowledge and experience continue to push the envelope in biotechnological research.
Conclusion
Benjamin Mijts stands out as a visionary inventor whose contributions to enzyme engineering and genetic editing technologies have the potential to transform various fields, including medicine, agriculture, and biotechnology. With a robust portfolio of patents and an impressive career trajectory, he remains a key player in the ongoing evolution of genetic engineering.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile